IRIS
MAIO, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.640
EU - Europa 13.734
AS - Asia 11.381
SA - Sud America 3.812
AF - Africa 487
OC - Oceania 53
Continente sconosciuto - Info sul continente non disponibili 11
Totale 51.118
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.306
SG - Singapore 4.395
RU - Federazione Russa 3.513
BR - Brasile 3.151
IE - Irlanda 2.510
CN - Cina 2.365
GB - Regno Unito 2.025
VN - Vietnam 1.918
IT - Italia 1.590
FR - Francia 1.294
HK - Hong Kong 1.151
UA - Ucraina 784
SE - Svezia 609
DE - Germania 476
IN - India 290
FI - Finlandia 286
AR - Argentina 244
ZA - Sudafrica 241
KR - Corea 228
BD - Bangladesh 195
ES - Italia 184
EC - Ecuador 126
MX - Messico 121
NL - Olanda 120
CA - Canada 115
ID - Indonesia 111
IQ - Iraq 107
AT - Austria 77
TR - Turchia 73
CO - Colombia 69
JP - Giappone 62
PK - Pakistan 54
SA - Arabia Saudita 54
VE - Venezuela 54
CL - Cile 51
AU - Australia 49
PY - Paraguay 48
PL - Polonia 47
UZ - Uzbekistan 39
KE - Kenya 38
MA - Marocco 38
AE - Emirati Arabi Uniti 33
AZ - Azerbaigian 31
EG - Egitto 31
MY - Malesia 31
NG - Nigeria 30
TN - Tunisia 30
UY - Uruguay 27
DZ - Algeria 26
CZ - Repubblica Ceca 25
PE - Perù 24
NP - Nepal 22
IL - Israele 21
KZ - Kazakistan 20
LT - Lituania 20
BE - Belgio 18
JO - Giordania 18
PA - Panama 18
AL - Albania 17
BO - Bolivia 17
CH - Svizzera 17
DO - Repubblica Dominicana 15
JM - Giamaica 15
OM - Oman 15
PH - Filippine 15
PT - Portogallo 15
GR - Grecia 14
IR - Iran 14
LB - Libano 14
CI - Costa d'Avorio 12
KG - Kirghizistan 12
BG - Bulgaria 11
ET - Etiopia 11
TW - Taiwan 11
SK - Slovacchia (Repubblica Slovacca) 10
XK - ???statistics.table.value.countryCode.XK??? 10
AM - Armenia 9
BH - Bahrain 9
CR - Costa Rica 9
HN - Honduras 9
HU - Ungheria 9
TH - Thailandia 9
BY - Bielorussia 8
DK - Danimarca 8
KW - Kuwait 8
LV - Lettonia 8
NO - Norvegia 8
PS - Palestinian Territory 8
RO - Romania 7
AO - Angola 6
KH - Cambogia 6
LK - Sri Lanka 6
SN - Senegal 6
SV - El Salvador 6
SY - Repubblica araba siriana 6
TT - Trinidad e Tobago 6
BA - Bosnia-Erzegovina 5
EE - Estonia 5
GE - Georgia 5
NI - Nicaragua 5
Totale 51.049
Salva come PNG Salva come JPEG
Città #
Fairfield 3.013
Dallas 2.892
Dublin 2.507
Singapore 2.052
Ashburn 1.663
Southend 1.630
Woodbridge 1.444
Wilmington 1.137
Seattle 1.131
Hong Kong 1.117
Houston 1.111
Cambridge 1.038
Moscow 910
Beijing 837
Jacksonville 753
Santa Clara 707
Ho Chi Minh City 608
San Jose 553
Princeton 533
Siena 411
Lauterbourg 408
The Dalles 401
Ann Arbor 400
Hanoi 366
San Mateo 358
Hefei 357
Dong Ket 280
Los Angeles 270
São Paulo 246
New York 241
Helsinki 226
Seoul 212
Dearborn 197
Council Bluffs 194
San Diego 194
Johannesburg 188
Chandler 168
Milan 166
Redondo Beach 133
Buffalo 132
Málaga 130
Shanghai 122
Florence 118
London 98
Rio de Janeiro 94
Rome 91
Nuremberg 90
Amsterdam 77
Da Nang 74
San Francisco 70
Orem 69
Chicago 63
Munich 63
Haiphong 61
Brasília 57
Belo Horizonte 56
Tokyo 56
Salvador 55
Dhaka 54
Frankfurt am Main 52
Curitiba 51
Bengaluru 47
Guayaquil 47
Phoenix 45
Delhi 44
Nanjing 44
Chennai 43
Porto Alegre 43
Stockholm 43
Toronto 43
Brooklyn 42
Campinas 42
Guarulhos 40
Norwalk 40
Vienna 40
Boardman 39
Guangzhou 39
Denver 38
Lappeenranta 36
Tashkent 36
Warsaw 35
Baghdad 33
Montreal 33
Quito 33
Goiânia 32
Buenos Aires 30
Hải Dương 30
Manchester 30
Riyadh 30
Thái Bình 30
Ninh Bình 29
Portsmouth 29
Baku 27
Biên Hòa 27
Fortaleza 26
Mexico City 26
Abuja 25
Boston 25
Düsseldorf 25
Atlanta 23
Totale 34.154
Salva come PNG Salva come JPEG
Nome #
Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team 471
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 342
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 327
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 313
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 253
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 252
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 245
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 243
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 242
Activity of ipilimumab at 10mg/kg in patients with advanced melanoma is independent of baseline prognostic factors 241
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial 238
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 236
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 236
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 220
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 220
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 219
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 218
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 217
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 216
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma 215
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 210
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy 210
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 208
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 206
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 205
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 204
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 204
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 202
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 201
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 198
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 196
Biomolecular strategies for therapeutic intervention in cancer 195
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 194
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 190
Biology and clinical applications of CD40 in cancer treatment 189
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 189
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: Evaluation of efficacy and tolerability 187
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised, double-blind, phase 3 trial 187
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 185
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 185
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma 185
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 184
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 184
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 183
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 180
Epigenetically-regulated Tumor-Associated Antigens in melanoma 180
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 180
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study 180
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade 179
A novel microRNA signature for the detection of melanoma by liquid biopsy 178
The biology of cancer testis antigens: putative function, regulation and therapeutic potential 177
Immunotherapy targeting immune check-point(s) in brain metastases 173
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 173
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 172
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" 171
5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? 171
Active immunization of melanoma patients with IL-2-transfected allogeneic melanoma cells. A phase I-II study 170
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide 170
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial 170
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story 170
Active immunization of melanoma patients with IL-2- or IL-4-transduced allogeneic melanoma cells 168
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study 168
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 167
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 166
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 166
Predictors of responses to immune checkpoint blockade in advanced melanoma 166
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab 166
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 165
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 163
Epigenetic drugs as immunomodulators for combination therapies in solid tumors 163
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 161
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 161
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells 160
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 159
The role of BRAF V600 mutation in melanoma 158
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 158
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications 157
Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies: Third Joint International Workshop, Lacco Ameno d'Ischia, Italy, October 2001 157
Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy 157
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 157
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 156
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients 155
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells 155
Future perspectives in melanoma research. Meeting report from the “Melanoma research: a bridge from Naples to the world. Napoli, December 5th-6th 2011” 155
Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody 155
Implementing liquid biopsies into clinical decision making for cancer immunotherapy 155
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) 154
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma 154
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? 153
5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation⇓positive advanced melanoma: Extended follow-up of the coBRIM study 153
Effects of cyclophosphamide and IL-2 on regulatory CD4(+) T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response 153
Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients 153
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications 153
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 153
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 152
Towards the introduction of the Immunoscore in the classification of malignant tumors 152
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009 151
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010" 151
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172) 150
Signaling by HLA class II antigens on B cells 150
Totale 18.945
Salva come PNG Salva come JPEG
Categoria #
all - tutte 187.197
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 187.197
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.205 0 0 0 0 0 0 0 0 0 422 195 588
2021/20223.530 179 419 383 96 44 160 121 153 223 523 373 856
2022/20233.127 408 171 642 400 76 694 85 122 156 142 170 61
2023/20243.525 92 77 268 87 83 1.001 1.212 110 62 37 64 432
2024/20258.384 331 377 442 477 745 323 110 296 947 1.038 1.108 2.190
2025/202619.303 1.472 3.010 2.561 3.308 3.554 642 2.269 778 759 950 0 0
Totale 52.348